Federal Register / Vol. 87, No. 112 / Friday, June 10, 2022 / Notices 35557 

clinical management of the cycle, which 

would include (but is not limited to) multiple 

aspects of the treatment such as patient 

selection, pre-treatment counseling and 

selection of the specific treatment protocol. 

The ART programs involved must have a 

method in place to ensure that these cycles 

can be prospectively reported by the ART 

program required to report them. In addition, 

all canceled cycles must be reported by the 

same ART program. 

b. Cycles involving previously 

cryopreserved oocytes/embryos are to be 

reported by the ART program that accepts 

responsibility for thawing the oocytes/ 

embryos. 

Dated: June 7, 2022. 

Angela K. Oliver, 

Executive Secretary, Centers for Disease 

Control and Prevention. 

[FR Doc. 2022–12528 Filed 6–9–22; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Administration for Children and 

Families 

Submission for OMB Review; 

Behavioral Interventions To Advance 

Self-Sufficiency Next Generation 

(BIAS–NG) (OMB# 0970–0502) 

AGENCY: Office of Planning, Research, 

and Evaluation, Administration for 

Children and Families, HHS. 

ACTION: Request for public comment. 

SUMMARY: The Office of Planning, 

Research, and Evaluation (OPRE) in the 

Administration for Children and 

Families (ACF), U.S. Department of 

Health and Human Services (HHS), 

requests Office of Management and 

Budget (OMB) approval to extend 

approval of the ACF Behavioral 

Interventions to Advance SelfSufficiency Next Generation (BIAS–NG) 

Project Overarching Generic (OMB #: 

0970–0502; Expiration date: 8/31/2022). 

Under this overarching generic, ACF 

collects data as part of rapid cycle 

testing and evaluation, in order to 

inform the design of interventions 

informed by behavioral science and to 

better understand the mechanisms and 

effects of such interventions. 

Interventions have been and will 

continue to be developed in the program 

area domains of Temporary Assistance 

for Needy Families (TANF), child 

welfare, and Early Head Start/Head Start 

(EHS/HS). These interventions are 

intended to improve outcomes for 

participants in these programs. No 

changes are proposed. 

DATES: Comments due within 30 days of 

publication. OMB must make a decision 

about the collection of information 

between 30 and 60 days after 

publication of this document in the 

Federal Register. Therefore, a comment 

is best assured of having its full effect 

if OMB receives it within 30 days of 

publication. 

ADDRESSES: Written comments and 

recommendations for the proposed 

information collection should be sent 

within 30 days of publication of this 

notice to www.reginfo.gov/public/do/ 

PRAMain. Find this particular 

information collection by selecting 

‘‘Currently under 30-day Review—Open 

for Public Comments’’ or by using the 

search function. You can also obtain 

copies of the proposed collection of 

information by emailing 

OPREinfocollection@acf.hhs.gov. 

Identify all requests by the title of the 

information collection. 

SUPPLEMENTARY INFORMATION: 

Description: OPRE is conducting the 

BIAS–NG project, which uses 

behavioral insights to design and test 

interventions intended to improve the 

efficiency, operations, and efficacy of 

human services programs. The BIAS– 

NG project is applying and testing 

behavioral insights to ACF programs 

including TANF, Child Welfare, and 

EHS/HS. This notice is a request for 

comments on ACF’s proposal to extend 

approval of the overarching generic. 

Under the approved pilot generic 

clearance, OPRE has already completed 

work with five sites and has conducted 

five tests. The extended approval would 

allow OPRE to continue to work with at 

least three additional sites, conducting 

one or more tests of behavioral 

interventions. The design and testing of 

BIAS–NG interventions is rapid and, to 

the extent possible, iterative. Each 

specific intervention is designed in 

consultation with agency leaders and 

launched as quickly as possible. To 

maximize the likelihood that the 

intervention produces measurable, 

significant, and positive effects on 

outcomes of interest, rapid cycle 

evaluation techniques will be employed 

in which proximate outcomes will be 

measured to allow the research team to 

more quickly iterate and adjust the 

intervention design, informing 

subsequent tests. Due to the rapid and 

iterative nature of this work, OPRE 

sought and received generic clearance to 

conduct this research. Following 

standard OMB requirements for generic 

clearances, once instruments requiring 

burden are tailored to a specific site and 

the site’s intervention, OPRE submits an 

individual generic information 

collection request under this umbrella 

clearance. Each request includes the 

individual instrument(s), a justification 

specific to the individual information 

collection, a description of the proposed 

intervention, and any supplementary 

documents. Each specific information 

collection includes up to two 

submissions—one submission for the 

formative stage research and another 

submission for any further data 

collection requiring burden during the 

testing phase. The type of information to 

be collected and the uses of the 

information is described in the 

supporting statements, found here: 

https://www.reginfo.gov/public/do/ 

PRAViewICR?ref_nbr=201909-0970-003. 

Respondents: (1) Program 

Administrators, (2) Program Staff, and 

(3) Program Clients. 

Annual Burden Estimates (TANF, CW, 

EHS/HS): This request includes an 

extension to complete currently 

approved and ongoing phase 3 data 

collection in three sites (Matrix/Starfish 

and Hennepin County), and new data 

collection. Burden estimates for new 

requests are outlined below. Previously 

approved burden estimates can be found 

at the url above. 

Instrument 

Number of 

respondents 

(TANF, CW, 

EHS/HS) 

(total over 

request 

period) 

Number of 

responses per 

respondent 

(total over 

request 

period) 

Average 

burden hours 

per response 

(in hours) 

Total burden 

(in hours) 

Annual burden 

(in hours) 

Phase 3: Diagnosis and Design 

Administrator interviews/focus groups ................................. 48 1 1 48 16 

Staff interviews/focus groups ............................................... 400 1 1 400 133 

Client interviews/focus groups ............................................. 400 1 1 400 133 

Client survey ........................................................................ 400 1 0.25 100 33 


jspears on DSK121TN23PROD with NOTICES1
35558 Federal Register / Vol. 87, No. 112 / Friday, June 10, 2022 / Notices 

Instrument 

Number of 

respondents 

(TANF, CW, 

EHS/HS) 

(total over 

request 

period) 

Number of 

responses per 

respondent 

(total over 

request 

period) 

Average 

burden hours 

per response 

(in hours) 

Total burden 

(in hours) 

Annual burden 

(in hours) 

Staff Survey ......................................................................... 400 1 0.25 100 33 

Phase 4: Evaluation 

Administrator interviews/focus groups ................................. 96 1 1 96 32 

Staff interviews/focus groups ............................................... 800 1 1 800 267 

Client interviews/focus groups ............................................. 800 1 1 800 267 

Client survey ........................................................................ 12,000 1 0.25 3,000 1,000 

Staff Survey ......................................................................... 1,200 1 0.25 300 100 

Estimated Total Annual Burden 

Hours: 2,014. 

Authority: 42 U.S.C. 1310. 

Mary B. Jones, 

ACF/OPRE Certifying Officer. 

[FR Doc. 2022–12538 Filed 6–9–22; 8:45 am] 

BILLING CODE 4184–07–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Small 

Business: Radiation Therapy and Biology 

SBIR/STTR. 

Date: July 7, 2022. 

Time: 9:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Bo Hong, Ph.D., Scientific 

Review Officer, Center for Scientific Review, 

National Institutes of Health, 6701 Rockledge 

Drive, Room 6194, MSC 7804, Bethesda, MD 

20892, 301–996–6208, hongb@csr.nih.gov. 

Name of Committee: Infectious Diseases 

and Immunology B Integrated Review Group; 

HIV Comorbidities and Clinical Studies 

Study Section. 

Date: July 12–13, 2022. 

Time: 9:00 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: David C. Chang, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Bethesda, MD 

20892, (301) 451–0290, changdac@

mail.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Small 

Business: Neuropathology, Developmental 

Disability, and Stem Education. 

Date: July 13–14, 2022. 

Time: 10:00 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Heidi B. Friedman, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 1012A, 

MSC 7770, Bethesda, MD 20892, (301) 379– 

5632, hfriedman@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; 

Fellowships: HIV/AIDS Biological. 

Date: July 14, 2022. 

Time: 10:00 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Raj K. Krishnaraju, Ph.D., 

MS Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 6190, 

MSC 7804, Bethesda, MD 20892, (301) 435– 

1047, kkrishna@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflict: Motivated Behavior, Alcohol and 

Neurotoxicology. 

Date: July 14, 2022. 

Time: 11:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Kirk Thompson, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5184, 

MSC 7844, Bethesda, MD 20892, 301–435– 

1242, kgt@mail.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflict: Metabolic Live Disease and 

Regeneration. 

Date: July 15, 2022. 

Time: 12:00 p.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Ganesan Ramesh, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 2182, 

MSC 7818, Bethesda, MD 20892, (301) 827– 

5467, ganesan.ramesh@nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Small 

Business: Biomedical Sensing, Measurement 

and Instrumentation. 

Date: July 19–20, 2022. 

Time: 9:00 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Michael L Bloom, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 6187, 

MSC 7804, Bethesda, MD 20892, 301–451– 

0132, bloomm2@mail.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Small 

Business: Innovative Immunology. 

Date: July 20, 2022. 

Time: 10:00 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Dayadevi Jirage, Ph.D. 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health 6701 Rockledge Drive, Room 809–H, 


jspears on DSK121TN23PROD with NOTICES1